Survival of XXXX with advanced @entity320 : The impact of novel therapies.

@entity1 @entity8047 @entity320 @entity8395 @entity817 @entity4386
UNASSIGNED: The survival of advanced @entity320 has been greatly improved within the past few years. New therapeutic strategies like kinase inhibitors for @entity817 -mutant @entity320 and immune checkpoint blockers proved to prolong survival times within clinical trials, and many of them have already entered routine clinical use. However, these different treatment modalities have not yet been tested against each other, which complicate  therapy decisions. We performed an explorative analysis of survival data from recent clinical trials. Thirty-five Kaplan-Meier survival curves from 17 trials were digitised, re-grouped by matching inclusion criteria and treatment line, and averaged by therapy strategy. Notably, the survival curves grouped by therapy strategy revealed a very high concordance, even if different agents were used. The greatest survival improvement was observed with the combination of @entity817 plus @entity8047 inhibitors as well as with @entity8395 ( @entity8395 ) blockers with or without @entity4386 ( @entity4386 ) blockers, respectively, with these two treatment strategies showing similar survival outcomes. For first-line therapy, averaged survival proportions of @entity1 alive at 12 months were 74.5% with @entity817 plus @entity8047 inhibitor treatment versus 71.9% with PD-1 blockade. This explorative comparison shows the kinase inhibitors as similarly effective as immune checkpoint blockers with regard to survival. However, to confirm these first trends for implementation into an individualised treatment of @entity320 @entity1 , data from prospective clinical trials comparing the different treatment strategies head-to-head have to be awaited.
